JP2010514669A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514669A5 JP2010514669A5 JP2009524039A JP2009524039A JP2010514669A5 JP 2010514669 A5 JP2010514669 A5 JP 2010514669A5 JP 2009524039 A JP2009524039 A JP 2009524039A JP 2009524039 A JP2009524039 A JP 2009524039A JP 2010514669 A5 JP2010514669 A5 JP 2010514669A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cells
- hla
- seq
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 81
- 210000004027 cell Anatomy 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 14
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 210000001808 exosome Anatomy 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 3
- 108010088729 HLA-A*02:01 antigen Proteins 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 description 21
- 108010074328 Interferon-gamma Proteins 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008177 pharmaceutical agent Substances 0.000 description 6
- 239000010432 diamond Substances 0.000 description 5
- 238000011510 Elispot assay Methods 0.000 description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 238000012286 ELISA Assay Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87861507P | 2007-01-03 | 2007-01-03 | |
| US60/878,615 | 2007-01-03 | ||
| US89647207P | 2007-03-22 | 2007-03-22 | |
| US60/896,472 | 2007-03-22 | ||
| PCT/JP2007/001466 WO2008081581A1 (en) | 2007-01-03 | 2007-12-26 | Foxp3 peptide vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514669A JP2010514669A (ja) | 2010-05-06 |
| JP2010514669A5 true JP2010514669A5 (cg-RX-API-DMAC7.html) | 2011-02-17 |
| JP5339375B2 JP5339375B2 (ja) | 2013-11-13 |
Family
ID=39588270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524039A Expired - Fee Related JP5339375B2 (ja) | 2007-01-03 | 2007-12-26 | Ｆｏｘｐ３ペプチドワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8563516B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2481748A3 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5339375B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090099075A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101641369B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007340834B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0720794A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2674365A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL199622A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009007261A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2473557C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG177199A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI441648B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008081581A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009050486A2 (en) * | 2007-10-19 | 2009-04-23 | The University Of Surrey | Peptide manipulators of regulatory t cell activity |
| CZ301144B6 (cs) * | 2008-09-15 | 2009-11-18 | Vysoká škola chemicko technologická v Praze | Príprava monoklonálních protilátek proti FoxP3 proteinu s použitím modifikovaných virum podobných cástic Masonova-Pfizerova opicího viru |
| MX2011006755A (es) * | 2008-12-24 | 2011-07-20 | Oncotherapy Science Inc | Peptidos clorf59 y vacunas que los incluyen. |
| TWI507204B (zh) * | 2009-05-26 | 2015-11-11 | Oncotherapy Science Inc | Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗 |
| AU2012296090B2 (en) * | 2011-08-12 | 2015-05-14 | Oncotherapy Science, Inc. | MPHOSPH1 peptides and vaccines including the same |
| CN102603892B (zh) * | 2012-02-22 | 2013-10-30 | 尉军 | 一种肿瘤标志物foxp3抗原多肽及应用 |
| JP7022067B2 (ja) * | 2016-01-14 | 2022-02-17 | メモリアル スローン ケタリング キャンサー センター | Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体 |
| CN111375055B (zh) * | 2020-02-20 | 2021-09-03 | 陈宛莎 | 一种2019-nCoV亚单位疫苗组合物及其免疫方法 |
| WO2025136809A2 (en) * | 2023-12-19 | 2025-06-26 | Regeneron Pharmaceuticals, Inc. | Foxp3 peptides and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3939746B2 (ja) | 1991-07-25 | 2007-07-04 | バイオジェン・アイデック・インコーポレイテッド | 細胞毒性ｔ−リンパ球応答の誘導 |
| WO2002090600A2 (en) * | 2001-05-08 | 2002-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
| CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| JP4628208B2 (ja) | 2004-08-10 | 2011-02-09 | オンコセラピー・サイエンス株式会社 | Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン |
| JP4840866B2 (ja) | 2005-01-19 | 2011-12-21 | 学校法人慶應義塾 | 癌ワクチン |
-
2007
- 2007-12-25 TW TW096149888A patent/TWI441648B/zh not_active IP Right Cessation
- 2007-12-26 BR BRPI0720794-8A patent/BRPI0720794A2/pt not_active IP Right Cessation
- 2007-12-26 CN CN200780051977.4A patent/CN101641369B/zh not_active Expired - Fee Related
- 2007-12-26 KR KR1020097015693A patent/KR20090099075A/ko not_active Abandoned
- 2007-12-26 JP JP2009524039A patent/JP5339375B2/ja not_active Expired - Fee Related
- 2007-12-26 RU RU2009129531/10A patent/RU2473557C2/ru not_active IP Right Cessation
- 2007-12-26 WO PCT/JP2007/001466 patent/WO2008081581A1/en not_active Ceased
- 2007-12-26 EP EP12153796A patent/EP2481748A3/en not_active Withdrawn
- 2007-12-26 SG SG2011091279A patent/SG177199A1/en unknown
- 2007-12-26 MX MX2009007261A patent/MX2009007261A/es active IP Right Grant
- 2007-12-26 CA CA002674365A patent/CA2674365A1/en not_active Abandoned
- 2007-12-26 US US12/522,066 patent/US8563516B2/en not_active Expired - Fee Related
- 2007-12-26 EP EP07849885A patent/EP2114987A4/en not_active Withdrawn
- 2007-12-26 AU AU2007340834A patent/AU2007340834B2/en not_active Ceased
-
2009
- 2009-06-30 IL IL199622A patent/IL199622A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514669A5 (cg-RX-API-DMAC7.html) | ||
| ES2378264T3 (es) | Péptido antigénico de unión a HLA-DR derivado de WT1 | |
| ES2545818T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
| ES2387685T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
| CN104168912B (zh) | 促进剂-dna组合疫苗 | |
| RU2011110504A (ru) | Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды | |
| CN101282742B (zh) | 脂质体在含连续疏水相的载体中作为癌症治疗媒介物的应用 | |
| RU2020113032A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2010523471A5 (cg-RX-API-DMAC7.html) | ||
| ES2900262T3 (es) | Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular | |
| JP2010506826A5 (cg-RX-API-DMAC7.html) | ||
| RU2009141595A (ru) | Пептиды тем8 и содержащие их вакцины | |
| JP2008530975A5 (cg-RX-API-DMAC7.html) | ||
| ES2566011T3 (es) | Péptido de epítopo HIG2 y URLC10 y vacunas que contienen el mismo | |
| ES2413079T3 (es) | Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral | |
| Fang et al. | The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model | |
| CN101754768B (zh) | 用作癌症疫苗的存活蛋白肽 | |
| RU2010110545A (ru) | Cdh3-пептид и включающее его лекарственное средство | |
| JP5717338B2 (ja) | 免疫療法のための潜在性ｈｌａ−ｂ７エピトープの同定、最適化及び使用 | |
| TWI441648B (zh) | Ｆｏｘｐ３胜肽疫苗 | |
| EP2576613A1 (en) | Her-2 peptides and vaccines | |
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| JP2010532656A (ja) | 癌退縮抗原ｎｙ−ｅｓｏ−１およびｌａｇｅ−１を含む融合タンパク質 | |
| AU2025204247A1 (en) | Large and small T antigens of merkel cell polyomavirus, nucleic acid constructs and vaccines made therefrom, and methods of using same | |
| RU2012136464A (ru) | Модифицированные пептиды melk и содержащие их вакцины |